Samsung Biologics said Tuesday it inked a partnership with Kurma Partners, a French venture capital firm specializing in financing health care companies, to offer a variety of drug-related services to Kurma Partners' portfolio companies. Under the partnership, Samsung Biologics will provide biotech companies invested in by Kurma Partners with its customizable chemical, manufacturing and control solutions. Custom.
Irish-US specialty pharmaceutical company Shorla Oncology has raised $35m (€33m) in funding from investors including private backers in Ireland and Enterprise Ireland.
CAMBRIDGE, Mass., October 04, 2023 Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, today announced that it has raised $35 million in Series B funding, led by Kurma Partners’ Growth Opportunities Fund, with participation from existing investors Seroba Life Sciences and Irish, U.S. and Canadian based family offices and Enterprise Ireland. The funding will enable Shorla to accelerate the growth of its oncology portfolio by advancing its pipeline, bringing therapies to
Kurma Partners announced the first closing of its Growth Opportunities fund at €160 million. Meeting the demand of the growing maturity of the European biotech and healthtech ecosystem, this new fund